Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04314713 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Intramuscular Administration of Scopolamine
A Phase 1 study, sponsored by Battelle Memorial Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT04314713 is a Phase 1 study that was terminated before completion, run by Battelle Memorial Institute. The registered enrollment target is 32 participants.
The verdict
NCT04314713, a Phase 1 study, was terminated before completion, sponsored by Battelle Memorial Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
To characterize the safety and tolerability profile of ascending doses of scopolamine hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection. And characterize the pharmacokinetics (PK) of ascending doses of Scopolamine HBT administered by IM injection
Interventions
- DRUG Scopolamine Hydrobromide Trihydrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2020-06-02 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04314713
The ClinicalTrials.gov registry entry for NCT04314713 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Battelle Memorial Institute, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Scopolamine Hydrobromide Trihydrate is the first listed.
NCT04314713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04314713 about?
NCT04314713 is a clinical study titled "A Study to Evaluate the Intramuscular Administration of Scopolamine". To characterize the safety and tolerability profile of ascending doses of scopolamine hydrobromide trihydrate (Scopolamine HBT) administered by intramuscular (IM) injection. And characterize the pharmacokinetics (PK) of ascending doses of Scopolamine HBT administered by IM injection
What is the current status of trial NCT04314713?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2020-06-02. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT04314713?
The interventions under investigation include: Scopolamine Hydrobromide Trihydrate (DRUG).
Who is sponsoring clinical trial NCT04314713?
This trial is sponsored by Battelle Memorial Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.